MX2022007807A - Conjugados de anticuerpo anti-egfr y farmaco. - Google Patents
Conjugados de anticuerpo anti-egfr y farmaco.Info
- Publication number
- MX2022007807A MX2022007807A MX2022007807A MX2022007807A MX2022007807A MX 2022007807 A MX2022007807 A MX 2022007807A MX 2022007807 A MX2022007807 A MX 2022007807A MX 2022007807 A MX2022007807 A MX 2022007807A MX 2022007807 A MX2022007807 A MX 2022007807A
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugates
- antibody drug
- egfr antibody
- adcs
- egfr
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 4
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a conjugados de anticuerpo y fármaco (ADC) anti-receptor del factor de crecimiento epidérmico (EGFR) que inhiben Bcl-xL, incluyendo composiciones y métodos de uso de dichos ADC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662347416P | 2016-06-08 | 2016-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007807A true MX2022007807A (es) | 2022-07-19 |
Family
ID=59078219
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018015286A MX2018015286A (es) | 2016-06-08 | 2017-06-07 | Conjugados de anticuerpo anti-egfr y farmaco. |
MX2022007807A MX2022007807A (es) | 2016-06-08 | 2018-12-07 | Conjugados de anticuerpo anti-egfr y farmaco. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018015286A MX2018015286A (es) | 2016-06-08 | 2017-06-07 | Conjugados de anticuerpo anti-egfr y farmaco. |
Country Status (21)
Country | Link |
---|---|
US (2) | US20190343961A1 (es) |
EP (2) | EP4104865A1 (es) |
JP (3) | JP2019521106A (es) |
KR (2) | KR20230035690A (es) |
CN (4) | CN116059201A (es) |
AU (1) | AU2017277517A1 (es) |
BR (1) | BR112018075636A2 (es) |
CA (1) | CA3027178A1 (es) |
CL (2) | CL2018003527A1 (es) |
CO (1) | CO2018013497A2 (es) |
CR (1) | CR20180614A (es) |
DO (2) | DOP2018000272A (es) |
EC (1) | ECSP19000157A (es) |
IL (3) | IL308054A (es) |
MX (2) | MX2018015286A (es) |
PE (1) | PE20190512A1 (es) |
PH (1) | PH12018502602A1 (es) |
RU (1) | RU2018147224A (es) |
SG (2) | SG10201914060WA (es) |
TW (2) | TW202320860A (es) |
WO (1) | WO2017214282A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3458479T3 (da) | 2016-06-08 | 2021-02-08 | Abbvie Inc | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater |
JP2019521975A (ja) * | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗egfr抗体薬物コンジュゲート |
EP3630189A4 (en) * | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | LINKER FOR ANTIBODY MEDICINAL CONJUGATES |
AU2020204250B2 (en) * | 2019-05-20 | 2021-04-08 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
TW202100184A (zh) | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體-藥物結合物及使用方法 |
KR20210097627A (ko) | 2020-01-30 | 2021-08-09 | 성균관대학교산학협력단 | 면역관문 억제제 및 엑소좀 분비 억제제를 포함하는 항체-약물 접합체 및 이를 포함하는 약학적 조성물 |
CN116137818A (zh) | 2020-05-19 | 2023-05-19 | 法国施维雅药厂 | 对-氨基-苄基接头、其制备方法及其在缀合物中的用途 |
KR20230143605A (ko) | 2020-11-24 | 2023-10-12 | 노파르티스 아게 | Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
EP4359440A1 (en) * | 2021-06-22 | 2024-05-01 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibody drug conjugates and uses thereof |
CN117580846A (zh) * | 2022-04-29 | 2024-02-20 | 石药集团中奇制药技术(石家庄)有限公司 | 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物 |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2023223097A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody drug conjugates |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1726514A (en) | 1926-11-01 | 1929-08-27 | Firm Ferd Liebschner & Sohn | Picker for looms |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE68921982D1 (de) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
AU2003256038A1 (en) | 2002-08-30 | 2004-03-19 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2005100584A2 (en) | 2004-04-15 | 2005-10-27 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
HUE057936T2 (hu) | 2005-07-18 | 2022-06-28 | Seagen Inc | Béta-glükuronid-linker-hatóanyag konjugátumok |
CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
US8399512B2 (en) | 2007-11-28 | 2013-03-19 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
CN102448469A (zh) | 2009-05-28 | 2012-05-09 | 摩萨纳医疗有限公司 | 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物 |
JP2013528665A (ja) | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
US8889675B2 (en) * | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
WO2013085925A1 (en) | 2011-12-05 | 2013-06-13 | Igenica, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
IN2014MN01488A (es) | 2011-12-23 | 2015-04-17 | Mersana Therapeutics Inc | |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
JP6423340B2 (ja) | 2012-05-15 | 2018-11-14 | シアトル ジェネティクス,インコーポレイティド | 自己安定化リンカー結合体 |
WO2014008375A1 (en) | 2012-07-05 | 2014-01-09 | Mersana Therapeutics, Inc. | Terminally modified polymers and conjugates thereof |
EP2928503B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugates of auristatin compounds |
JP6334553B2 (ja) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス,インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
BR112016021717A2 (pt) | 2014-03-21 | 2018-07-10 | Abbvie Inc | anticorpos anti-egfr e conjugados anticorpo-fármaco |
CN111620862A (zh) * | 2014-12-09 | 2020-09-04 | 艾伯维公司 | Bcl-xl抑制性化合物和包括其的抗体药物缀合物 |
KR20170093943A (ko) | 2014-12-09 | 2017-08-16 | 애브비 인코포레이티드 | 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체 |
CN107249643A (zh) * | 2014-12-09 | 2017-10-13 | 艾伯维公司 | 具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物 |
-
2017
- 2017-06-07 CN CN202211269635.2A patent/CN116059201A/zh active Pending
- 2017-06-07 CA CA3027178A patent/CA3027178A1/en active Pending
- 2017-06-07 SG SG10201914060WA patent/SG10201914060WA/en unknown
- 2017-06-07 TW TW111128039A patent/TW202320860A/zh unknown
- 2017-06-07 IL IL308054A patent/IL308054A/en unknown
- 2017-06-07 CN CN202211269863.XA patent/CN116059394A/zh active Pending
- 2017-06-07 CR CR20180614A patent/CR20180614A/es unknown
- 2017-06-07 EP EP22166591.2A patent/EP4104865A1/en active Pending
- 2017-06-07 RU RU2018147224A patent/RU2018147224A/ru not_active Application Discontinuation
- 2017-06-07 CN CN201780048216.7A patent/CN109563168A/zh active Pending
- 2017-06-07 MX MX2018015286A patent/MX2018015286A/es unknown
- 2017-06-07 US US16/308,463 patent/US20190343961A1/en not_active Abandoned
- 2017-06-07 WO PCT/US2017/036368 patent/WO2017214282A1/en unknown
- 2017-06-07 EP EP17731394.7A patent/EP3468996B1/en not_active Withdrawn - After Issue
- 2017-06-07 CN CN202211269794.2A patent/CN116059202A/zh active Pending
- 2017-06-07 PE PE2018003191A patent/PE20190512A1/es unknown
- 2017-06-07 JP JP2018564215A patent/JP2019521106A/ja active Pending
- 2017-06-07 KR KR1020237007108A patent/KR20230035690A/ko active Application Filing
- 2017-06-07 SG SG11201810970WA patent/SG11201810970WA/en unknown
- 2017-06-07 AU AU2017277517A patent/AU2017277517A1/en active Pending
- 2017-06-07 BR BR112018075636-9A patent/BR112018075636A2/pt unknown
- 2017-06-07 TW TW106118952A patent/TW201806626A/zh unknown
- 2017-06-07 KR KR1020197000330A patent/KR20190015526A/ko active IP Right Grant
-
2018
- 2018-12-07 MX MX2022007807A patent/MX2022007807A/es unknown
- 2018-12-07 IL IL263571A patent/IL263571A/en unknown
- 2018-12-07 CL CL2018003527A patent/CL2018003527A1/es unknown
- 2018-12-07 DO DO2018000272A patent/DOP2018000272A/es unknown
- 2018-12-10 PH PH12018502602A patent/PH12018502602A1/en unknown
- 2018-12-13 CO CONC2018/0013497A patent/CO2018013497A2/es unknown
-
2019
- 2019-01-03 EC ECSENADI2019157A patent/ECSP19000157A/es unknown
- 2019-08-09 CL CL2019002270A patent/CL2019002270A1/es unknown
-
2021
- 2021-09-10 US US17/447,362 patent/US20230077680A1/en active Pending
- 2021-12-13 JP JP2021201460A patent/JP2022058351A/ja active Pending
-
2022
- 2022-03-02 IL IL291073A patent/IL291073A/en unknown
- 2022-09-09 DO DO2022000182A patent/DOP2022000182A/es unknown
-
2023
- 2023-08-10 JP JP2023130710A patent/JP2023166395A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502602A1 (en) | Anti-egfr antibody drug conjugates | |
MX2021010471A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
MX2018015280A (es) | Conjugados de anticuerpo y farmaco anti-egfr. | |
MX2018015284A (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
PH12017500451A1 (en) | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide | |
TW202423486A (zh) | 抗egfr抗體藥物結合物 | |
MX2018005376A (es) | Derivados de azetidina para formacion de imágenes de tau. |